• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    飯

    飯塚病院

    Aso Iizuka Hospital
    EST. 1918
    1,070论文总数
    1.9万引用总数

    论文量&引用量时间轴

    机构学者

    论文(1070)

    年份
    起
    –
    止
    排序
    1Identification of Risk Factors for the Local Recurrence of Hepatocellular Carcinoma Post-radiofrequency Ablation.
    Kosuke Tanaka,Akifumi Kuwano,Masayoshi Yada,Hideo Suzuki,Kenta Motomura

    BACKGROUND/AIM:Radiofrequency ablation (RFA) is a mainstay curative treatment for unresectable hepatocellular carcinoma (HCC). Despite the success of RFA, however, some patients with HCC continue to experience local recurrence (LR). The aim of the present study was to identify risk factors for LR post-RFA, considering cases of repeated RFA for LR-HCC separately. PATIENTS AND METHODS:This study initially included 829 patients who underwent RFA for HCC at our institution between January 2013 and December 2022. From these, 447 patients with single HCC were selected based on the selection criteria, and they were further classified into a new HCC lesion group (n=400, NL group) and repeated RFA for LR-HCC post-first RFA group (n=47, LR group). The two groups were retrospectively analyzed to identify factors related to LR post-RFA. RESULTS:In the NL and LR groups, the median observation period after treatment was 36.9 months and 33.7 months, respectively. The cumulative LR rates were 5.1%, 11.0%, and 14.2% in the NL group, and 12.8%, 34.2%, and 40.8% in LR group at 1, 3, and 5 years post-RFA, respectively. The Cox proportional hazard test showed that HCC tumors >1.5 cm [hazard ratio (HR)=3.606; p=0.001] and tumor site (adjacent to blood vessels) (HR=1.932; p=0.035) were identified as independent risk factors for LR post-RFA in the NL group, while only TACE prior to RFA was identified in the LR group. CONCLUSION:Tumor size and site of HCC were independent risk factors for LR post-RFA. Moreover, repeated RFA for LR-HCC post-first RFA had quite a high rate of LR post-RFA. For these cases, the selection of modalities other than RFA should be considered.

    2026Anticancer research(2026)
    引用
    AI阅读
    加入学术空间
    2Efficacy and Safety of RApid PrednIsolone Dose Reduction for Acute Exacerbation of Idiopathic Pulmonary Fibrosis (RAPID-IPF Trial): a Study Protocol for a Randomised Controlled Trial
    Keisuke Anan,Yuki Kataoka,Masataka Taguri,Kazuya Ichikado,Ryo Tachikawa,Kazunori Tobino,Kodai Kawamura,Chigusa Shirakawa,Takafumi Kawabata,Yosuke Yamamoto

    Introduction Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a life-threatening event with high mortality. While systemic corticosteroids are commonly used in clinical practice for AE-IPF despite the absence of randomised evidence, the optimal tapering strategy is uncertain. Early corticosteroid tapering reduces adverse events in other inflammatory diseases. However, the efficacy and safety of this approach in AE-IPF have not been established. This study aims to determine if an early corticosteroid tapering regimen is non-inferior to a conventional regimen for 90-day mortality in patients with AE-IPF.Methods and analysis The RApid PrednIsolone Dose reduction for acute exacerbation of Idiopathic Pulmonary Fibrosis (RAPID-IPF) trial is a multicentre, parallel-group, open-label, randomised controlled non-inferiority trial conducted in Japan. A total of 70 patients (up to 130) hospitalised for AE-IPF will be randomly assigned in a 1:1 ratio to either an accelerated 6-week prednisolone tapering regimen (early tapering group) or a conventional 12-week tapering regimen (standard tapering group). The primary outcome is all-cause mortality at 90 days. The non-inferiority margin is set at a 10% risk difference. Key secondary outcomes include 28-day mortality, mortality due to respiratory causes, time to respiratory worsening or death, protocol adherence and the proportion of patients lost to follow-up. The trial incorporates two interim analyses for feasibility and sample size re-estimation.Ethics and dissemination This study will be conducted in compliance with the Declaration of Helsinki and Japanese ethical guidelines. The protocol was approved by the institutional review boards of all participating hospitals (lead approval: Saiseikai Kumamoto Hospital, #1367). Written informed consent will be obtained from all participants or their legally acceptable representatives. Findings will be disseminated through scientific conferences and publication in a peer-reviewed journal.Trial registration number Japan Registry of Clinical Trials (jRCT1071250015).

    2026BMJ open respiratory research(2026)
    引用
    AI阅读
    加入学术空间
    3Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.
    Akifumi Kuwano,Masayoshi Yada,Kosuke Tanaka, Taikan Hamamoto, Ryotaro Tanaka,Kazuki Kurosaka,Hideo Suzuki,Kenta Motomura

    BACKGROUND/AIM:Immune checkpoint inhibitor-based combination therapies are standard treatment options for unresectable hepatocellular carcinoma (HCC). However, conventional endpoints such as objective response rate, progression-free survival, and overall survival may not fully capture response dynamics, including depth of response (DpR), time to response, and duration of response. This study descriptively evaluated response dynamics in patients with unresectable HCC treated with durvalumab plus tremelimumab or atezolizumab plus bevacizumab. PATIENTS AND METHODS:This retrospective single-center study included 148 patients with unresectable HCC who received durvalumab-tremelimumab (n=53) or atezolizumab-bevacizumab (n=95). A reduction of ≥50% in target lesion diameter was defined as DpR50. Because of baseline imbalances and differences in observation period, the analysis was only descriptive and hypothesis-generating. RESULTS:Fifty-three patients received durvalumab-tremelimumab and 95 received atezolizumab-bevacizumab. The overall response rate was 35.8% for the durvalumab-tremelimumab group and 27.4% for the atezolizumab-bevacizumab group, whereas the disease control rates were 54.7% and 71.6%, respectively. DpR50 was observed in 26.4% and 11.6% of patients, respectively. The median times to response were 2.3 and 3.3 months, and the median durations of response were 22.3 and 10.0 months, respectively. Durable response lasting ≥6 months occurred in 24.5% and 15.8% of all treated patients, respectively. The median PFS was 5.2 and 7.0 months, and median OS was 17.0 and 22.0 months, respectively. CONCLUSION:Therapy with durvalumab-tremelimumab was associated with deeper and more durable tumor shrinkage in selected responders, whereas atezolizumab-bevacizumab provided broader disease control mainly through stable disease. These findings should be interpreted as hypothesis-generating.

    2026Anticancer research(2026)
    引用
    AI阅读
    加入学术空间
    4ASO Visual Abstract: Prediction of Tracheobronchial Invasion in Yct3 Esophageal Cancer Using Contact Angle on Preoperative CT Images: A Multicenter Analysis
    Tomonori Nakanoko, Tetsuro Kawazoe,Kosuke Hirose,Qingjiang Hu,Yasuo Tsuda, Yuki Shin,Keita Natsugoe, Naomichi Koga,Sho Nambara, Kensuke Kudou,Koji Ando, Yasue Kimura,
    2026Annals of Surgical Oncology(2026)
    引用
    AI阅读
    加入学术空间
    5
    鴻 酒井, 祐介 久保, 高之 打道, 優一朗 沖﨑, 敬祐 小宮山, 和彦 園田, 辰彦 美浦, 晶彦 浜崎, 俊彦 原
    2026Orthopedics &amp Traumatology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1070 篇论文

    合作机构(100)

    九州大学合作论文 270
    库卢梅大学合作论文 52
    京都大学合作论文 47
    福冈大学合作论文 46
    済生会福岡総合病院合作论文 40
    顺天堂大学合作论文 36
    Hamanomachi Hospital合作论文 35
    近畿大学合作论文 32
    九州大学医院合作论文 32
    National Kyushu Medical Center,National Hospital Organization合作论文 32

    机构统计